공시 • Jun 30
Tern Plc Appoints Jane Mccracken as Interim Chair Tern Plc announced that Jane McCracken, previously an independent Non-Executive Director of the Company, assumed the role of the Company's Chair at the conclusion of the AGM, initially on an interim basis. The Board of the Company now therefore comprises Jane McCracken (Independent Interim Non-Executive Chair) and Iain Ross (Independent Non-Executive Director). The Board will continue to be supported by a non-Board senior management team, led by Al Sisto and Bruce Leith. 공시 • Jun 07
Tern Plc, Annual General Meeting, Jun 30, 2025 Tern Plc, Annual General Meeting, Jun 30, 2025. Location: the offices of allenby capital, 5 st helens place, ec3a 6ab, london United Kingdom 공시 • Jun 06
Tern PLC Announces Ian Ritchie Decides to Retire from its Board, Effective June 30, 2025 Tern PLC announced that Ian Ritchie, who has been the Company's Non-Executive Chairman since 2017, has decided to retire from the Board at the conclusion of the AGM to be held on June 30, 2025. Board Change • Nov 04
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Chairman Ian Ritchie was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 공시 • Oct 30
Tern plc Announces Board Changes Tern Plc announced a number of changes to the Company's Board of Directors (the "Board"). Tern announced the appointment of Jane Karwoski (known as "Jane McCracken") and Iain Ross as independent Non-Executive Directors of the Company with immediate effect. Sarah Payne and Alan Howarth have stepped down from the Board with immediate effect to concentrate on their other business interests. Following these changes the Board now comprises Ian Ritchie (Non-Executive Chairman), Jane McCracken (Non-Executive Director) and Iain Ross (Non-Executive Director). Jane McCracken has spent her career working with high growth technology businesses based in the USA. UK and Europe as an entrepreneur, investor, board member and advisor. Her experience covers a variety of areas including software, e-commerce, digital health and clinical research. She recently served as an Entrepreneur-in-Residence at the Advanced Technology Development Center, the state incubator based at Georgia Institute of Technology. She is the Chief Growth Officer for Corps Team, a US-based search and staffing firm supporting startups to the Fortune 500. Jane also serves on the board of London Stock Exchange Main Market listed Edinburgh Worldwide Investment Trust plc, which invests globally in high growth companies; and Radyus Research, a US-based privately held company that advises on drug discovery, lead candidate selection, and enabling studies. Iain Ross has over 40 years' experience in the international life sciences and technology sectors and has held significant roles in multi-national pharmaceutical and biotech companies. He has completed multiple financing transactions and has over 30 years' experience in cross-border management as a chairman or CEO. He has led or participated in eight IPOs and has direct experience of M&A transactions in Europe, the USA and the Pacific Rim. Currently he is Chairman of NASDAQ listed Silence Therapeutics plc, Executive Chairman of ReNeuron Group plc and internationally holds other non-executive director roles. Iain Ross joined the board of Redx Pharma plc on 1 May 2017. On 24 May 2017, Redx Pharma plc and Redx Oncology Ltd. were put into administration by Liverpool City Council, whilst Iain Ross was a director of both companies, as a result of non-payment of an outstanding loan of £2m. On 3 November 2017 Redx Pharma plc and Redx Oncology Ltd. exited administration with all creditors paid, under the Chairmanship of Iain Ross.Iain Ross was a director of Palla Pharma Limited, a company registered in Tasmania Australia, when it entered into administration on 17 December 2021. Subsequently in March 2022, a liquidator was appointed for a creditors' voluntary liquidation process. Iain Ross resigned from the board of Palla Pharma Limited on 20 April 2022. Iain Ross is Chairman of ReNeuron Group plc and director of its three subsidiaries, ReNeuron (UK) Limited, ReNeuron Holdings Limited, ReNeuron Limited, all of which entered into administration on 20 March 2024. This process is currently ongoing and Iain Ross remains the Chairman of ReNeuron Group plc and a director of the three above subsidiaries. 공시 • May 31
Tern Plc, Annual General Meeting, Jun 27, 2024 Tern Plc, Annual General Meeting, Jun 27, 2024. Location: the offices of allenby capital, 5 st helens place, ec3a 6ab, london United Kingdom